ULCERATIVE COLITIS& CROHN'S DISEASECLINICAL TRIAL
Evaluating the safety and efficacy of a novel JAK inhibitor for patients with moderate to severe inflammatory bowel disease in New York City.
Study Overview
Ulcerative Colitis and Crohn's Disease are chronic inflammatory bowel diseases (IBD) that affect millions worldwide. Many patients continue to experience symptoms despite available treatments. This clinical research study evaluates the safety and efficacy of a novel JAK inhibitor — a targeted oral therapy designed to modulate the immune system and reduce intestinal inflammation, potentially offering a new treatment option for patients with moderate to severe IBD.
Duration
36-48 Weeks
Target Group
Adults 18-75
Participants must meet the following criteria to be eligible for the study:
- Age 18-75 years old
- Diagnosed with moderate to severe ulcerative colitis or Crohn's disease for at least 3 months
- Currently experiencing active symptoms despite conventional treatment
- Previous treatment with standard anti-inflammatory medications
- Stable medication regimen for at least 4 weeks prior to screening
- Willing to maintain current diet and lifestyle habits during the study
- Able to attend regular clinic visits and follow study procedures
- Provide written informed consent
Apply Now
See if you qualify for this study
Participant Safety is Our Priority
Ethical Oversight
All studies are reviewed and approved by an Institutional Review Board (IRB) to ensure participant safety and rights.
Informed Consent
We provide clear, detailed information about the study before you decide to participate, and you can withdraw at any time.
Expert Monitoring
Participants receive regular health check-ups and are closely monitored by our team of medical professionals.